Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113602 | 1.00 | LMNA (0.52) | LMNAL3MBTL1SRCPLA2G7PPARG | |
| SCHEMBL10797604 | 1.00 | LMNA (0.52) | LMNAL3MBTL1SRCPLA2G7PPARG | |
| SCHEMBL13397720 | 0.87 | SRC (0.61) | LMNASRCPPARGPPARANPC1 | |
| SCHEMBL14572074 | 0.87 | SRC (0.48) | LMNAL3MBTL1SRCPLA2G7PPARG | |
| SCHEMBL28173018 | 0.87 | SRC (0.48) | LMNAL3MBTL1SRCPLA2G7PPARG | |
| SCHEMBL14572076 | 0.83 | NPC1 (0.55) | LMNAL3MBTL1SRCPPARGPPARA | |
| Propane SCHEMBL11032480 | 0.82 | PPARG (0.41) | LMNAL3MBTL1SRCPLA2G7PPARG | |
| Propene SCHEMBL11100982 | 0.82 | SRC (0.41) | LMNAL3MBTL1SRCPLA2G7PPARG | |
| SCHEMBL2901541 | 0.81 | LMNA (0.48) | LMNAL3MBTL1PLA2G7NPC1RAB9A | |
| SCHEMBL28484755 | 0.81 | LMNA (0.48) | LMNAL3MBTL1PLA2G7NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | claimed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | claimed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | claimed |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| WO-2025151874-A1 | INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12083186-B2 | Methods for assembling scavenging particles | NANOTICS, LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240269319-A1 | METHODS FOR ASSEMBLING SCAVENGING PARTICLES | NANOTICS, LLC | 2024-08-15 | — | — | US | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024147060-A1 | NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY | CELON PHARMA S.A. (PL) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024145281-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20070149551-A1 | 5-PHENYLPYRIMIDINES, THEIR PREPARATION, COMPOSITIONS COMPRISING THEM AND THEIR USE | GYPSER ANDREAS | 2007-06-28 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2007013965-A2 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| EP-0369334-A2 | 1-Aminoalkyl-3-oxysubstituted-4-aryl-1,3,4,5-tetrahydro-2H-1,3-benzodiazepine-2-ones, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4908360-A | Hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149551-A1 | 5-PHENYLPYRIMIDINES, THEIR PREPARATION, COMPOSITIONS COMPRISING THEM AND THEIR USE | CBR1, CBR3, NTPCR | LMNA 2453/4885L3MBTL1 2590/4885SRC 2465/4885 |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | LMNA 3612/4885L3MBTL1 722/4885SRC 1353/4885 |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | LMNA 4420/4885L3MBTL1 3727/4885SRC 1497/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | LMNA 870/4885L3MBTL1 131/4885SRC 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.